Loading…

Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System

Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may...

Full description

Saved in:
Bibliographic Details
Published in:Nephron 2021, Vol.145 (4), p.392-403
Main Author: Banoun, Helene
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913
cites cdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913
container_end_page 403
container_issue 4
container_start_page 392
container_title Nephron
container_volume 145
creator Banoun, Helene
description Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.
doi_str_mv 10.1159/000515417
format article
fullrecord <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_proquest_journals_2522353377</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2519798562</sourcerecordid><originalsourceid>FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</originalsourceid><addsrcrecordid>eNptkd1r2zAUxUXpaEPXh72PYejLBvOmK1lffSiEkC6FbINk3atQHKlxa1upZKf0v69NOncrexKc-7vnSDoIvQP8BYCprxhjBiwDcYBGhFCWUpD8EI2Ac5xKYHCMTmO87TBCgSqaHaFjShVgAjBC8-nOl21T-DrxLlmOF8t04n-n5DxZ2F1hH3r1e9uYnoifk4UvbS81G5vMfGySq6pqa5ssH2Njq7fojTNltKfP5wm6vpz-mszS-c9vV5PxPM0ZI00qnFIiyxg4xmiegbRYSkGVcW5FsCOCC2mFc44RQclqzajlhAuDcxA8V0BP0MXed9uuKrvObd0EU-ptKCoTHrU3hf53UhcbfeN3WpJMSIo7g097g82rtdl4rnsNUwKMK9j1YR-fw4K_b21sdFXE3Jalqa1voyYMlFCScdKhZ6_QW9-GuvuKjuq7oVSIl_A8-BiDdcMNAOu-Uj1U2rEf_n7pQP4psAPe74E7E25sGIBh_-y_4x_Tyz2ht2tHnwDq8awE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522353377</pqid></control><display><type>article</type><title>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</title><source>Coronavirus Research Database</source><creator>Banoun, Helene</creator><creatorcontrib>Banoun, Helene</creatorcontrib><description>Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.</description><identifier>ISSN: 1660-8151</identifier><identifier>ISSN: 2235-3186</identifier><identifier>EISSN: 2235-3186</identifier><identifier>EISSN: 1660-2137</identifier><identifier>EISSN: 1660-2110</identifier><identifier>DOI: 10.1159/000515417</identifier><identifier>PMID: 33910211</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adaptive immunology ; COVID-19 - immunology ; COVID-19 - virology ; Emerging diseases ; Experimental Nephrology and Genetics: Review ; Experimental Nephrology and Genetics: Review Article ; Human health and pathology ; Humans ; Immune System ; Immunology ; Infectious diseases ; Innate immunity ; Life Sciences ; Microbiology and Parasitology ; Mutation ; Pandemics ; SARS-CoV-2 - genetics ; SARS-CoV-2 - immunology ; Virology</subject><ispartof>Nephron, 2021, Vol.145 (4), p.392-403</ispartof><rights>2021 S. Karger AG, Basel</rights><rights>2021 S. Karger AG, Basel.</rights><rights>2021. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.karger.com/Tap/Home/278492 Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</citedby><cites>FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2522353377?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,780,784,885,27925,38516,43895</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2522353377?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33910211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03215691$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Banoun, Helene</creatorcontrib><title>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</title><title>Nephron</title><addtitle>Nephron</addtitle><description>Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.</description><subject>Adaptive immunology</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>Emerging diseases</subject><subject>Experimental Nephrology and Genetics: Review</subject><subject>Experimental Nephrology and Genetics: Review Article</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immune System</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Innate immunity</subject><subject>Life Sciences</subject><subject>Microbiology and Parasitology</subject><subject>Mutation</subject><subject>Pandemics</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS-CoV-2 - immunology</subject><subject>Virology</subject><issn>1660-8151</issn><issn>2235-3186</issn><issn>2235-3186</issn><issn>1660-2137</issn><issn>1660-2110</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNptkd1r2zAUxUXpaEPXh72PYejLBvOmK1lffSiEkC6FbINk3atQHKlxa1upZKf0v69NOncrexKc-7vnSDoIvQP8BYCprxhjBiwDcYBGhFCWUpD8EI2Ac5xKYHCMTmO87TBCgSqaHaFjShVgAjBC8-nOl21T-DrxLlmOF8t04n-n5DxZ2F1hH3r1e9uYnoifk4UvbS81G5vMfGySq6pqa5ssH2Njq7fojTNltKfP5wm6vpz-mszS-c9vV5PxPM0ZI00qnFIiyxg4xmiegbRYSkGVcW5FsCOCC2mFc44RQclqzajlhAuDcxA8V0BP0MXed9uuKrvObd0EU-ptKCoTHrU3hf53UhcbfeN3WpJMSIo7g097g82rtdl4rnsNUwKMK9j1YR-fw4K_b21sdFXE3Jalqa1voyYMlFCScdKhZ6_QW9-GuvuKjuq7oVSIl_A8-BiDdcMNAOu-Uj1U2rEf_n7pQP4psAPe74E7E25sGIBh_-y_4x_Tyz2ht2tHnwDq8awE</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Banoun, Helene</creator><general>S. Karger AG</general><general>Karger</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>COVID</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope></search><sort><creationdate>2021</creationdate><title>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</title><author>Banoun, Helene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptive immunology</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>Emerging diseases</topic><topic>Experimental Nephrology and Genetics: Review</topic><topic>Experimental Nephrology and Genetics: Review Article</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immune System</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Innate immunity</topic><topic>Life Sciences</topic><topic>Microbiology and Parasitology</topic><topic>Mutation</topic><topic>Pandemics</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS-CoV-2 - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banoun, Helene</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Coronavirus Research Database</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nephron</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Banoun, Helene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</atitle><jtitle>Nephron</jtitle><addtitle>Nephron</addtitle><date>2021</date><risdate>2021</risdate><volume>145</volume><issue>4</issue><spage>392</spage><epage>403</epage><pages>392-403</pages><issn>1660-8151</issn><issn>2235-3186</issn><eissn>2235-3186</eissn><eissn>1660-2137</eissn><eissn>1660-2110</eissn><abstract>Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>33910211</pmid><doi>10.1159/000515417</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1660-8151
ispartof Nephron, 2021, Vol.145 (4), p.392-403
issn 1660-8151
2235-3186
2235-3186
1660-2137
1660-2110
language eng
recordid cdi_proquest_journals_2522353377
source Coronavirus Research Database
subjects Adaptive immunology
COVID-19 - immunology
COVID-19 - virology
Emerging diseases
Experimental Nephrology and Genetics: Review
Experimental Nephrology and Genetics: Review Article
Human health and pathology
Humans
Immune System
Immunology
Infectious diseases
Innate immunity
Life Sciences
Microbiology and Parasitology
Mutation
Pandemics
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Virology
title Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A32%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolution%20of%20SARS-CoV-2:%20Review%20of%20Mutations,%20Role%20of%20the%20Host%20Immune%20System&rft.jtitle=Nephron&rft.au=Banoun,%20Helene&rft.date=2021&rft.volume=145&rft.issue=4&rft.spage=392&rft.epage=403&rft.pages=392-403&rft.issn=1660-8151&rft.eissn=2235-3186&rft_id=info:doi/10.1159/000515417&rft_dat=%3Cproquest_COVID%3E2519798562%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2522353377&rft_id=info:pmid/33910211&rfr_iscdi=true